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with both pulmonary involvement and cryoglobulinemia. Therefore, this study was designed to
investigate the relationship between pulmonary involvement and mixed cryoglobulinemia in chronic
HCV infected patients and to investigate the role of TNF-alpha in the pathogenesis of pulmonary
changes.
Subjects and methods: After hospital ethics committee approval and formal patient consent were
obtained, 100 patients with compensated hepatitis C virus infection as conﬁrmed by PCR were
recruited in this cross sectional study. Their demographic and laboratory data, abdominal ultra-
sound ﬁndings, pulmonary function tests (spirometry), arterial blood gas (ABG) parameters,
TNF-alpha levels, and data from high-resolution chest CT were collected and analyzed using SPSS
version 16, and a serum cryoglobulin assay was performed in all of the studied patients.5621176; fax: 20 50 2260138.
.com, im4.med@sghgroup.net
e Egyptian Society of Chest
g by Elsevier
ng by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and Tuberculosis.
://dx.doi.org/10.1016/j.ejcdt.2013.11.017
260 AbdelBaset M. Saleh et al.Results: The prevalence of mixed cryoglobulinemia was 61.7% in the studied HCV patients. Pul-
monary symptoms were observed in more than half of these patients. The most common complaint
among the symptomatic patients was dyspnea (51.7%), followed by cough (43.3%). Oxygen satu-
ration (Spo2 and Sao2%), and FEV1 and FVC levels, were signiﬁcantly decreased in the cryoglob-
ulin positive patients compared to the cryoglobulin negative patients. A statistically signiﬁcant
correlation was found between the presence of cryoglobulins and FEV1 level, FVC level, serum
albumin level, viremia level, thrombocytopenia and arterial blood gas parameters. No correlation
was found between cryoglobulinemia and TNF-alpha level.
Conclusions: The results of this study suggest that pulmonary involvement is common in patients
with chronic HCV infection and mixed cryoglobulinemia. Cryoglobulinemia may lead to pulmon-
ary involvement through vascular and interstitial deposition of cryoglobulins, which results in
impaired gas exchange and airway affection.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Chronic hepatitis C virus (HCV) infection is a major public
health problem worldwide, and more than 170 million people
are chronically infected with HCV (approximately 3% of the
world’s population) [1]. In Egypt, the situation is quite worse
because the overall anti-HCV antibody prevalence is 14.7%
[2].
HCV predominantly affects the liver; however, it can also
produce a number of extra hepatic manifestations, such as
mixed cryoglobulinemia (MC), which is the most common
and severe extra hepatic manifestation. HCV is a systemic
vasculitis involving the small- and medium-sized arteries and
veins. MC is characterized by the deposition of immune
complexes containing mainly rheumatoid factor, IgG, HCV
RNA, and complement on endothelial surfaces, causing
vascular inﬂammation through poorly understood mecha-
nisms [3]. Moreover, many inﬂammatory diseases are known
to be associated with the overproduction of cytokines such
as TNF-alpha. TNF-alpha performs several proinﬂammatory
functions including the promotion of leukocyte–endothelium
interactions and the activation of the arachidonic acid
pathway [4].
The prevalence of mixed cryoglobulinemia is related to
the endemic presence of HCV infection, and its prevalence
varies widely between countries, ranging from 10–70%; this
geographical heterogeneity may be due to population selec-
tion and time lead bias [1]. Chronic HCV infected cryoglob-
ulinemic patients have an apparent duration of HCV
infection that is almost twice as long as that in chronic
HCV infected non cryoglobulinemic patients, thereby sug-
gesting that MC is associated with an increased duration
of HCV infection [5].
Many MC patients are asymptomatic. MC is diagnosed
when a patient has a typical organ involvement (mainly skin,
kidney, or peripheral nerves) in addition to circulating
cryoglobulins. Cutaneous purpura is the most common mani-
festation of cryoglobulinemic vasculitis. The most frequently
affected internal organs are the peripheral nerves, kidneys,
lungs and joints [6].
Pulmonary involvement in MC is usually mild, although
severe pulmonary complications including diffuse alveolar
damage, organizing pneumonia and hemoptysis have beenreported [7]. However, a few studies have demonstrated pul-
monary involvement in chronic HCV infection with and with-
out cryoglobulinemia; the prevalence of pulmonary
involvement in MC is not well understood.
Therefore, this studywas designed to investigate the relation-
ship between pulmonary involvement andmixed cryoglobuline-
mia in chronic HCV infected patients and to investigate the role
of TNF-alpha in the pathogenesis of pulmonary changes.
Understanding the epidemiology of the relationship between
pulmonary involvement and mixed
cryoglobulinemia in chronic HCV infected patients and the
pathogenesis of pulmonary changes will provide novel insights
into better management, especially in the present era of liver
transplantation, in which the presence of advanced pulmonary
affection may be considered as a major hurdle in the treatment
of chronic HCV infected patients.
Materials and methods
Study design
This was a cross sectional study including 100 patients with
compensated HCV infection (69 males and 31 females) with
mean age 54.63 years.
Sample size and power of the study
The sample size was calculated using the medcalc program
available at www.medcalc.be on 21-2-2011. The conﬁdence
level for our study was 95% with an alpha error of 0.05. The
power of this study was set at 80% with a beta error of
20%. The maximum prevalence of mixed cryoglobulinemia
was considered to be 60%. The minimal prevalence of mixed
cryoglobulinemia was considered to be 50%. The estimated
sample size was 195 patients. Two hundred forty patients with
chronic HCV infection were screened for study eligibility, and
100 patients were recruited in the study according to the inclu-
sion and exclusion criteria.
This study was performed at the Tropical Medicine
Department, in collaboration with the Thoracic Medicine,
Clinical Pathology, Pathology and Radiology Departments,
Mansoura University Hospital, between May 2010 and
December 2011. One hundred patients with chronic HCV
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tests were included.
Patient selection
This study included a convenient sample of patients such as
those attending the inpatient and outpatient clinics of the
Tropical Medicine Unit, and all of the patients provided writ-
ten informed consent. The Institutional Review Board (IRB)
of our Faculty of Medicine approved the study.
Inclusion criteria for patient selection were as follows:
1. Adults
2. Any gender
3. Egyptian nationality
4. HCV infection documented by PCR
5. Abnormal liver function tests
 The patient group was further subdivided into two
subgroups according to the presence or absence of
cryoglobulinemia (mean age of HCV infected cryonega-
tive patients was 45.5 ± 5.89 years and that of
HCV infected cryopositive patients was 47.8 ±
7.98 years).
Exclusion criteria were as follows:
 Patients with decompensated liver disease (i.e. ascites,
encephalopathy and coagulopathy which are the signs
of liver cell failure).
 Patients with previous lung disease (prior to the diagno-
sis of HCV).
 Smokers.
 Patients with previous systemic diseases (such as renal
failure, congestive heart failure and connective tissue
disorders).
 Patients with a current history or past history of anti-
viral treatment for hepatitis C.
 Patients with autoimmune liver diseases or any other
liver disease.
All of the patients were subjected to the following:
Thorough history taking and clinical examination, sero-
logic assays and PCR for HCV and HBs Ag, liver function
tests and alpha fetoprotein (AFP) test for screening of hep-
ato-cellular carcinoma (HCC) were performed. Abdominal
ultrasound and triphasic CT abdomen were also performed.
To assess the severity of liver disease, liver biopsy was per-
formed according to Ishak et al. [8] scoring system.
In addition, all of the patients were subjected to arterial
blood gas (ABG) analysis, pulmonary function tests (spirome-
try) and chest high resolution CT scan (HRCT).
Arterial blood gas analysis
ABG samples were obtained by a percutaneous radial artery
puncture in stable seated patients while breathing room air.
Then, the pH, partial pressure of oxygen in arterial blood
(PaO2), partial pressure of carbon dioxide in arterial blood
(PaCO2) and other parameters were measured with a standard
blood gas analyzer (Eschweiler compact PGA, serial No.
P2084, GERMANY).Pulmonary function tests
Forced expiratory volume in ﬁrst second (FEV1), forced vital
capacity (FVC), forced mid-expiratory ﬂow rate (FEF25-75),
and FVC/FEV1% were measured and recorded using a spi-
rometer by a trained, experienced chest physician. Spirometry
was performed in accordance with American Thoracic Society
criteria. Three technically acceptable measurements were ob-
tained for each patient, and the highest value was included
in the analyses (Spirolab 2, serial No.A23–050.09978MIR,
ITALY)
Cryoglobulin testing
Cryoglobulins were detected by the Winﬁeld method [9].
Twenty milliliters of venous blood was obtained from each pa-
tient in a pre-warmed (37 C) syringe. The blood was allowed
to clot at 37 C, and the serum was separated by centrifuga-
tion. The supernatant was incubated at 4 C for 8 d and was
examined daily for the cryoprecipitate.
Assessment of tumor necrosis factor-alpha (TNF-alpha) levels
The evaluation of serum TNF-alpha levels was performed
using a commercially available enzyme-linked immunosorbent
assay, human TNF-alpha ELISA kit (RayBio, GA, USA),
according to the manufacturer’s instructions.
Liver biopsy. Liver biopsy specimens were ﬁxed in 10% forma-
lin, and theywere stainedwith hematoxylin, eosin andMasson’s
trichrome. The specimens with more than six portal areas were
used for examination. The severity of chronic liver disease
(CLD) was estimated according to Ishak et al. [8] scoring system
proposed in 1995 (ﬁbrosis 0–6, and liver biopsy was suitable).
Statistical analysis
The statistical package for the Social Sciences (SPSS) version
16 was used for the statistical analysis. The qualitative data
were presented in the form of numbers and percentages. The
Chi-square test was used as a test of signiﬁcance for the qual-
itative data, and Yates correction was used when the expected
cell count was less than 5. The quantitative data were ex-
pressed as mean and standard deviation. Independent sample
t test was used to compare the quantitative data between
two groups. Pearson correlation was used to study the rela-
tionship between variables. Statistical signiﬁcance was consid-
ered at a p value less than 0.05.
Results
This study showed that the prevalence of cryoglobulinemia
was 61.7% in the studied HCV patients.
Table 1 summarizes the patients’ clinical data. Pulmonary
symptoms were found in less than half of the patients;
however, there was no difference in the pulmonary symptoms
between the cryoglobuin positive patients and the cryoglobulin
negative patients. Dyspnea and cough were the most common
complaints among the symptomatic patients. Some patients
had more than one pulmonary symptom. A statistically
signiﬁcant difference was found in the extra pulmonary
manifestations, such as vasculitis, rash, renal impairment,
Table 1 Clinical data of the studied compensated HCV patients according to the presence or absence of cryoglobulins.
Cryoglobulin positive
patients (n= 52) N (%)
Cryoglobulin negative
patients (n= 48) N (%)
Test of
signiﬁcance
Renal involvement 4 (8.3) – P= 0.034
DM 28 (58.3) 8 (15.4) P< 0.001
Arthralgia 16 (33.3) 4 (7.7) P= 0.002
Elevated purpura (vasculitis rash) 24 (50) 8 (15.4) P< 0.001
Lichen planus 4 (8.3) – P= 0.034
Lower limb pigmentation 20 (41.7) 12 (23.1) P= 0.046
Cough 20 (41.7) 16 (30.8) P= 0.177
Dyspnea 20 (41.7) 20 (38.5) P= 0.45
262 AbdelBaset M. Saleh et al.arthralgia, lichen planus and diabetes, between the cryoglobu-
lin positive patients and the cryoglobulin negative patients.
Table 2 summarizes the lung function abnormalities (diag-
nosed by ABG analysis and spirometry) and laboratory
ﬁndings of the HCV patients with and without cryoglobuline-
mia. The Spo2, Sao2%, FEV1 and FVC levels were signiﬁ-
cantly decreased in the cryoglobulin positive compensated
HCV patients as compared to the cryoglobulin negative com-
pensated HCV patients; however, the clinical data showed no
difference between the groups in terms of age, sex and disease
duration.
There was a signiﬁcant increase in the serum albumin level
and viremia level in the cryo-positive HCV patients, whereas
liver enzymes (ALT and AST) were signiﬁcantly elevated in
the cryo-negative HCV patients.
However, the comparison of chest HRCT ﬁndings in both
the groups showed no signiﬁcant difference. The non-septal
lines, pulmonary vascular congestion and septal lines were
the most common chest HRCT ﬁndings, followed by ground
glass attenuation. Some patients showed more than one abnor-
mality on chest HRCT.
Table 3 shows that there was a statistically signiﬁcant cor-
relation between the presence of cryoglobulins and FEV1 level,Table 2 Clinical data, blood gas analysis, pulmonary function test
according to the presence or absence of cryoglobulins.
Cryoglobulin negative patients (n= 48)
Age (Mean ± SD) 45.5 ± 5.89
Disease duration (years) 10.5 ± 3.23
Gender male/female 30/18
ABG
PaO2 (mmHg) 130.5 ± 29.31
O2 saturation 97.71 ± 1.63
pH 7.37 ± 0.148
PaCO2 (mmHg) 35.66 ± 6.41
Pulmonary function tests
FEV1/FVC (%) 98.15 ± 12.72
FEV1 (% predicted) 89.61 ± 11.45
FVC (% predicted) 88.53 ± 12.96
FEF25–75 97.84 ± 15.92
Laboratory tests
Bilirubin (mg/dL) 0.98 ± 0.20
ALT (IU/dL) 78.58 ± 60.67
AST (IU/dL) 90.16 ± 72.43
S. Albumin (g/dL) 3.9 ± 0.64
HCV viral load (IU/ml) 222.33 ± 304.51FVC level, serum albumin level, viremia level, thrombocytope-
nia and arterial blood gas parameters (PaO2 and O2 satura-
tion). No signiﬁcant correlation was found between the
presence of cryoglobulins and pulmonary symptoms (such
as, cough and wheezing) or extra-pulmonary ﬁndings (such
as, arthralgia, purpura, lichen planus and lower limb vasculi-
tis). Finally, as shown in Table 3, there were signiﬁcant
negative correlations between cryoglobulin positivity and
ALT and AST levels; however, no correlation was found be-
tween cryoglobulin positivity and other liver function tests.
Hepatic ﬁbrosis was evaluated using the Ishak score; it
showed a signiﬁcant correlation with pulmonary function
parameters, including FEV1/FVC, O2 saturation and PaO2
(P values 0.005, 0.026, respectively), whereas no signiﬁcant
correlation was found between ﬁbrosis score and cryoglobulin-
emia (Data not shown).
Table 4 demonstrates the TNF-alpha levels in both the
cryonegative patients and the cryopositive patients, which
may indicate the underlying pathophysiological role of TNF-
alpha in causing pulmonary changes.
The median TNF-alpha level in the cryopositive patients
was higher than that in the cryonegative patients; however, this
difference was not statistically signiﬁcant.s and laboratory tests of the studied compensated HCV patients
Cryoglobulin positive patients (n= 52) Test of signiﬁcance
47.8 ± 7.98 P= 0.115
11.3 ± 4.34 P= 0.163
39/13 P= 0.66
83.5 ± 36.1 P< 0.001
92.7 ± 4.57 P< 0.001
7.39 ± 0.042 P= 0.73
32.04 ± 8.08 P= 0.25
104.81 ± 1.37 P= 0.081
79.16 ± 16.72 P= 0.013
76.41 ± 21.86 P= 0.020
73.83 ± 0.83 P= 0.003
0.96 ± 0.32 P= 0.96
59 ± 15.61 P= 0.027
65.38 ± 24.29 P= 0.022
4.15 ± 0.49 P= 0.035
440.27 ± 337 P< 0.001
Table 3 Correlation between the presence of cryoglobulins, clinical and laboratory data, pulmonary function tests (PFT) and arterial
blood gas parameters (ABG) in the compensated HCV patient group.
Clinical data Presence of
cryoglobulins
Laboratory
data
Presence of
cryoglobulins
PFT &
ABG
Presence of
cryoglobulins
Diabetes mellitus 0.103 ALT 0.226 PaO2 0.59
Arthralgia 0.115 AST 0.242 O2
saturation
0.56
Elevated purpura 0.107 Serum albumin 0.20
Lichen planus 0.189 FEV1/FVC 0.22
Lower limb
pigmentation
0.104 FEV1 0.389
Cough 0.05 HCV viral load 0.226 FVC 0.341
Wheezing 0.189 Thrombo-
cytopenia
0.390 FEF25–75 0.248
Table 4 Serum TNF-alpha levels (pg/ml) in the studied compensated HCV patient groups.
Cryoglobulin negative compensated HCV
patient group (n= 48)
Cryoglobulin positive compensated HCV
patient group (n= 52)
Control (n= 72) P value
TNF-alpha 34.39 ± 8.29 39.89 ± 19.11 22.42 ± 6.19 <0.001
Cryoglobulin negative compensated HCV patient group versus Control (P< 0.001).
Cryoglobulin positive compensated HCV patient group versus Control (P< 0.001).
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This study showed that mixed cryoglobulinemia is prevalent in
HCV patients (61.7%). Oxygen saturation (Spo2 and Sao2%),
and FEV1 and FVC levels were signiﬁcantly decreased in the
cryoglobulin positive patients than in the cryoglobulin nega-
tive patients. A statistically signiﬁcant correlation was found
between the presence of cryoglobulins and FEV1 level, FVC le-
vel, serum albumin level, viremia level, thrombocytopenia and
arterial blood gas parameters.
This study showed that the prevalence of mixed cryoglobu-
linemia was 61.7% in the studied HCV patients. This result is
within the range of the previous estimates for the prevalence of
MC in HCV infection, which varies widely from 10% to 70%.
According to different studies, MC can be found in 19–50% of
patientswithHCV infection. At the same time, only a small frac-
tion of these HCV infected patients (less than 15%) have symp-
tomatic mixed cryoglobulinemia. However, the asymptomatic
mixed cryoglobulinemic patients may develop CG-related
symptoms during the course of the disease. Factors that seem
to favor the development ofMC are female gender, age, alcohol
intake (>50 g/d), advanced liver ﬁbrosis and steatosis [10–12].
HCV is a well-known cause of liver ﬁbrosis, and it could
potentially provoke similar abnormalities in the lung, mainly
because of its lymphotropism, which can induce chronic im-
mune activation and inﬂammation [13]. Importantly, in this
study, pulmonary symptoms were found in more than half of
the patients. Dyspnea, which is the main symptom of pulmon-
ary interstitial affection, was the most common complaint
among the symptomatic patients (51.7%), followed by cough
in 43.3% and expectoration in 1.7% of patients. Some patients
had more than one pulmonary symptom. Our ﬁndings are in
agreement with those of previous studies which reported that
HCV infection was complicated by a number of extrahepatic
manifestations, and it is associated with both the obstructive
and restrictive lung diseases [14,15]. However, for some accom-panying disorders, such as mixed cryoglobulinemia, the patho-
genetic role of the HCV is substantiated by the epidemiologic
and experimental data [16,17].
Importantly, a signiﬁcant increase was found in the serum
albumin level (thereby increasing blood viscosity) and HCV
viremia levels in the cryo-positive patients, which suggest an
increased deposition of cryoglobulins in the pulmonary inter-
stitial tissue and in the airway. These ﬁndings are manifested
by impaired gas exchange and obstructive ventilatory defect.
In addition, these ﬁndings are in agreement with those of a
previous study, which reported that the most common clinical
features of hepatitis C associated with mixed cryoglobulinemia
(MC+ HCV) are correlated with those of vasculitis affecting
various organs and sometimes with those of an increased vis-
cosity of the plasma [18]. Many MC+HCV patients experi-
ence symptoms, such as fatigue, dyspnea and reduced
physical activity. However, in many patients, these symptoms
are not proportional to the liver involvement [18].
Some evidence suggests that alveolitis and HCV infection
may not be coincidental ﬁndings [19,20]. In addition, the prev-
alence of serum antibodies against HCV (determined using
ﬁrst-generation enzyme-linked immunosorbent assay) has been
reported to be higher in patients with idiopathic pulmonary
ﬁbrosis (IPF) than in controls, although a subsequent study
using similar but improved techniques refuted this ﬁnding
[21,22]. Further evidence of an association between HCV
and interstitial lung involvement was provided by Ferri et al.
[23]. Our study reported a signiﬁcant two fold increase in the
HCV viremia levels in the cryo-positive patients compared
with the cryo-negative patients.
Mixed cryoglobulinemia is a well-described complication
of HCV infection [24]. Fibrotic lung disease is likely to re-
sult from an inciting injurious event within the lung. How-
ever, the sequence of events and mechanisms of ﬁbrotic
lung disease are not understood. An emerging hypothesis
is that occult infections may play a pathogenetic role as
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this hypothesis is based on the assumption that an inﬂam-
matory agent (such as a virus) disrupts the physiologic
healing response, thereby making the lung highly susceptible
to injurious triggers [25]. Chronic HCV infection may con-
tribute to the immune responses that modulate the patho-
genic processes underlying pulmonary disorders; therefore,
chronic HCV infection may produce a wide spectrum of
clinical presentations. The inﬂammatory cytokines are the
potential candidates that play a role in these immune re-
sponses [26].
In this study, both cryoglobulinemic patients and non cryo-
globulinemic patients showed signiﬁcantly higher mean TNF-
alpha levels than those in controls; however, no signiﬁcant
difference in the mean TNF-alpha levels was demonstrated be-
tween cryoglobulinemic and non cryoglobulinemic patients.
On the other hand, another study reported signiﬁcantly higher
serum TNF-alpha levels in the HCV–MC patients than in
HCV+ patients or in controls [18]. In addition, other studies
reported elevated serum levels of B cell-activating factor
(BAFF), a TNF-alpha family member, which is required for
B cell survival in HCV–MC, although the underlying mecha-
nism remains unclear [27–30].
Thus, our study conﬁrmed the ﬁnding of a high serum
TNF-alpha level in HCV +ve patients with or without cryo-
globulinemia, as was previously demonstrated in other studies
of HCV +ve patients [31–33]. The increase in the TNF-alpha
level in MC+ HCV patients was unlikely to be due to a more
aggressive liver disease; in fact, in our study, no correlation
was found between the TNF-alpha levels and ALT levels, or
between the TNF-alpha levels and the degree of liver inﬂam-
mation. This result was in accordance with that of a previous
study [34]. Other studies have shown an increased production
of TNF-alpha by lymphocytes in MC+HCV patients [35,36],
thereby suggesting that the increase in the TNF-alpha level
may be due to the activation of lymphoid cells.
However, the severity of pulmonary involvement may or
may not parallel the liver impairment; thus, patient manage-
ment and prediction of disease outcome can be subject to
marked variability. Therefore, early referral of MC+ HCV
patients who complain of any pulmonary symptoms to a spe-
cialized medical team in this ﬁeld (pulmonologists and hepatol-
ogists) is strongly recommended.
Our study has two limitations. First, the study population
may not be a representative of the general population in Egypt.
Therefore, this study may have been affected by the selection
bias. Second, genotyping of HCV and cryoglobulin quantita-
tion were not performed because there was not enough ﬁnan-
cial aid to cover these expenses in the studied HCV cases.
Conclusion
Cryoglobulinemia is a laboratory ﬁnding, and it is not a clin-
ical presentation. Cryoglobulinemia may have an impact on
both gas exchange and airway parameters. Understanding
the respiratory effects of HCV, which is considered to be a ma-
jor health problem in Egypt, might improve our approach in
the treatment of respiratory problems complicating HCV. Fu-
ture studies should focus on evaluating the pathophysiological
mechanisms underlying the relationship between mixed cry-
globulinemia and pulmonary affection in chronic HCV
patients.Conﬂict of interest
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